IL-18 treatment reduced alcohol-elevated plasma ALT and AST levels (ALT levels: AF 78.9 ± 16.6 U/L vs. AF+IL-18 41.8 ± 15.4 U/L, p < 0.05; AST levels: AF 62.9 ± 14.3 U/L vs. AF+IL-18 35.4 ± 11.1 U/L, p < 0.05). This evidence concerns the gene GPT and atrial fibrillation.